First-line treatment for advanced or recurrent thymic cancer
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of an immunotherapy drug (ivonescimab) plus chemotherapy as the first treatment for people with advanced or recurrent thymic cancer. The goal is to see how well this combination works and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have thymic cancer that has spread (metastatic) or come back (recurrent) and cannot be removed with surgery.
- You have not received any prior treatment for this cancer (this will be your first treatment).
- You are generally able to take care of yourself (ECOG performance status 0-1) and expected to live at least 3 more months.
- You have adequate organ function, including blood counts, kidney, liver, heart, and thyroid function.
- You have not had immunotherapy (like PD-1/PD-L1 inhibitors) or anti-angiogenic drugs before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ivonescimab for thymic carcinoma that has come back or isn't responding to other treatments. It aims to see if this drug can shrink the cancer and help you feel better.
This trial tests a combination of ivonescimab and docetaxel for people with advanced non-small cell lung cancer who have had a long response (11-15 months without the cancer getting worse) to first-line immunotherapy. The goal is to see if adjusting treatment based on ctDNA-MRD levels can improve outcomes.
This trial tests a new combination of three medicines (two chemotherapies and an immunotherapy) for people with a certain type of advanced lung cancer called squamous non-small cell lung cancer. The goal is to see if this combo can help shrink or control the cancer better than current treatments.
This trial tests a new immunotherapy drug called ivonescimab given together with standard chemotherapy for advanced stomach cancer. It may help your immune system fight the cancer more effectively.
This study tests a new immunotherapy drug called ivonescimab given before surgery for people with advanced head and neck cancer. The goal is to see if it helps shrink the tumor and improve outcomes.
This trial studies ivonescimab alone as a first treatment for people with advanced non-small cell lung cancer (NSCLC) that tests positive for PD-L1 and doesn't have certain gene changes. The goal is to see if it works and is safe in everyday medical practice.
Hear when a new First-line Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.